ReviewiScience2026
Liquid-liquid phase separation in cancer therapy resistance.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid-liquid phase separation (LLPS) has emerged as a fundamental mechanism that orchestrates essential cellular functions. Emerging evidence has established a compelling link between LLPS and core oncogenic processes, including cancer initiation, metastasis, immune evasion, and therapeutic resistance. Among these processes, treatment resistance remains a major barrier to achieving sustained clinical benefit. Aberrant biomolecular condensates formed via LLPS are increasingly recognized as critical mediators of multiple therapy resistance pathways and can be as promising therapeutic targets to overcome treatment failure. In this review, we synthesize emerging insights into how LLPS-derived biomolecular condensates contribute to therapy resistance through diverse mechanisms. We highlight therapeutic strategies aimed at disrupting or exploiting condensate dynamics for reversing cancer therapy resistance. By bridging phase separation biology with resistance mechanisms, this review offers a conceptual framework to assist future research and therapeutic development in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.